Skip to content
1887
Volume 63, Issue 3
  • ISSN: 2056-5135
Preview this article:

There is no abstract available.

Loading

Article metrics loading...

/content/journals/10.1595/205651319X15579077595864
2019-01-01
2024-03-28
Loading full text...

Full text loading...

/deliver/fulltext/jmtr/63/3/Dilley_16a_Imp.html?itemId=/content/journals/10.1595/205651319X15579077595864&mimeType=html&fmt=ahah

References

  1. Brennan Z. ‘FDA Allows First Switch From Batch to Continuous Manufacturing for HIV Drug’, Regulatory Focus™, Regulatory Affairs Professionals Society, Rockville, Maryland, USA, 12th April, 2016 LINK https://www.raps.org/regulatory-focus%E2%84%A2/news-articles/2016/4/fda-allows-first-switch-from-batch-to-continuous-manufacturing-for-hiv-drug [Google Scholar]
  2. ‘Quality Considerations for Continuous Manufacturing’, Docket Number: FDA-2019-D-0298, US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Rockville, MD, USA, February, 2019 LINK https://www.fda.gov/regulatory-information/search-fda-guidance-documents/quality-considerations-continuous-manufacturing LINK https://www.fda.gov/media/121314/download [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.1595/205651319X15579077595864
Loading
  • Article Type: Research Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error